Literature DB >> 18812916

Anterior-only approaches to scoliosis.

Mohammed F Shamji1, Robert E Isaacs.   

Abstract

Scoliosis is a three-dimensional spinal deformity for which surgery may be indicated when patients experience severe pain, curve progression, or progressive disability. Operative treatment has conventionally involved extensive posterior stabilization, either alone or in combination with anterior release procedures. Anterior-only approaches have a more limited role, but they should be considered in the appropriate setting when addressing this disease. Some advantages of anterior-only approaches to scoliosis include greater corrective ability with a greater fusion rate while mandating fewer motion segments to be involved in the instrumented construct. Preventing denervation of the posterior paraspinal musculature is also desirable and is inherently provided for by the anterior approach. Disadvantages include pulmonary morbidity associated with violating the thoracic cavity, as well as post-thoracotomy chronic pain. There are also limitations in the indications for which anterior-only surgery can be performed, and these will be discussed along with treatment options. Technological advances, including minimally invasive thoracic access as well as evolving instrumentation, may minimize the stated disadvantages and expand the scope of scoliosis cases that may be treated by anterior-only approaches. Hence, the enhanced corrective ability and biomechanical advantages of the anterior column can be used in the treatment of these patients. Although the indications for anterior-only strategies in scoliosis remain limited, such operations should be considered in the appropriate setting when addressing spinal deformity.

Entities:  

Mesh:

Year:  2008        PMID: 18812916     DOI: 10.1227/01.NEU.0000325486.92090.DA

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  8 in total

1.  Answer to the Letter to the Editor of A. Gardner concerning "Comparison of combined anterior-posterior approach versus posterior-only approach in treating adolescent idiopathic scoliosis: a meta-analysis" by Chen Z, Rong L (2016) Eur Spine J;25(2):363-371.

Authors:  Zihao Chen; Limin Rong
Journal:  Eur Spine J       Date:  2016-11       Impact factor: 3.134

2.  Two-year radiographic and clinical outcomes of a minimally invasive, lateral, transpsoas approach for anterior lumbar interbody fusion in the treatment of adult degenerative scoliosis.

Authors:  Kaveh Khajavi; Alessandria Y Shen
Journal:  Eur Spine J       Date:  2014-03-12       Impact factor: 3.134

3.  Clinical evaluation of microendoscopy-assisted extreme lateral interbody fusion.

Authors:  Tomohide Segawa; Hirohiko Inanami; Hisashi Koga
Journal:  J Spine Surg       Date:  2017-09

4.  Substantial clinical benefit of minimally invasive lateral interbody fusion for degenerative spondylolisthesis.

Authors:  Kaveh Khajavi; Alessandria Shen; Anthony Hutchison
Journal:  Eur Spine J       Date:  2015-03-24       Impact factor: 3.134

5.  Approach-related lesions of the sympathetic chain in anterior correction and instrumentation of idiopathic scoliosis.

Authors:  Tobias L Schulte; Bastian Mester; Denise Oberdiek; Nani Osada; Ulf Liljenqvist; Timm J Filler; Martin Marziniak; Viola Bullmann
Journal:  Eur Spine J       Date:  2010-05-26       Impact factor: 3.134

6.  Extreme lateral interbody fusion (XLIF) approach for L5-S1: Preliminary experience.

Authors:  Junjie Xu; Enliang Chen; Le Wang; Xiaobao Zou; Chenfu Deng; Junlin Chen; Rencai Ma; Xiangyang Ma; Zenghui Wu
Journal:  Front Surg       Date:  2022-09-27

7.  Clinical outcome and fusion rates after the first 30 extreme lateral interbody fusions.

Authors:  Gregory M Malham; Ngaire J Ellis; Rhiannon M Parker; Kevin A Seex
Journal:  ScientificWorldJournal       Date:  2012-11-01

8.  Posterior-only spinal fusion without rib head resection for treating type I neurofibromatosis with intra-canal rib head dislocation.

Authors:  Dong Sun; Fei Dai; Yao Yao Liu; Jian-Zhong Xu
Journal:  Clinics (Sao Paulo)       Date:  2013-12       Impact factor: 2.365

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.